Johnson & Johnson (NYSE:JNJ) Shares Sold by Cascade Investment Advisors Inc.

Cascade Investment Advisors Inc. reduced its position in Johnson & Johnson (NYSE:JNJGet Rating) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,133 shares of the company’s stock after selling 177 shares during the quarter. Cascade Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $1,391,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Capital Investment Counsel Inc raised its position in shares of Johnson & Johnson by 0.8% during the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock worth $1,334,000 after buying an additional 59 shares in the last quarter. Beaton Management Co. Inc. raised its position in shares of Johnson & Johnson by 0.3% during the 4th quarter. Beaton Management Co. Inc. now owns 22,250 shares of the company’s stock worth $3,806,000 after buying an additional 60 shares in the last quarter. Iron Horse Wealth Management LLC raised its position in shares of Johnson & Johnson by 29.9% during the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after buying an additional 61 shares in the last quarter. Magnus Financial Group LLC raised its position in shares of Johnson & Johnson by 0.8% during the 3rd quarter. Magnus Financial Group LLC now owns 8,074 shares of the company’s stock worth $1,304,000 after buying an additional 63 shares in the last quarter. Finally, Benchmark Financial Wealth Advisors LLC raised its position in shares of Johnson & Johnson by 3.7% during the 4th quarter. Benchmark Financial Wealth Advisors LLC now owns 1,774 shares of the company’s stock worth $303,000 after buying an additional 63 shares in the last quarter. 68.78% of the stock is owned by institutional investors.

In other Johnson & Johnson news, insider William Hait sold 29,699 shares of the company’s stock in a transaction dated Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the sale, the insider now directly owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Thibaut Mongon sold 23,681 shares of the company’s stock in a transaction dated Thursday, March 17th. The stock was sold at an average price of $176.25, for a total transaction of $4,173,776.25. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

NYSE JNJ traded down $1.02 during midday trading on Friday, hitting $176.85. The company had a trading volume of 7,732,163 shares, compared to its average volume of 7,745,147. The firm has a fifty day simple moving average of $177.92 and a two-hundred day simple moving average of $170.40. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The stock has a market cap of $465.36 billion, a price-to-earnings ratio of 23.83, a P/E/G ratio of 2.91 and a beta of 0.66.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, beating analysts’ consensus estimates of $2.60 by $0.07. The business had revenue of $23.43 billion during the quarter, compared to analyst estimates of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.59 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 10.2 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, May 23rd. This represents a $4.52 dividend on an annualized basis and a yield of 2.56%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s payout ratio is presently 57.14%.

JNJ has been the topic of a number of research reports. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 6th. Raymond James boosted their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Sanford C. Bernstein lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their price target for the company from $180.00 to $183.00 in a report on Wednesday, March 16th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 30th. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $203.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Buy” and an average target price of $188.57.

About Johnson & Johnson (Get Rating)

Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.